Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Getting the right drug into the right patient

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Pharmaceutical Researchers and Manufacturers of America.

  2. 2

    Poirer, J. et al. 1995. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 92: 12260–12264.

    Article  Google Scholar 

  3. 3

    Farlow, M.R. et al. 1996. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann. N.Y. Acad. Sci. 802: 101–110.

    Article  Google Scholar 

  4. 4

    Richard, F. et al. 1997. APOE genotyping and response to drug treatment in Alzheimer's disease. Lancet 349: 539.

    Article  Google Scholar 

  5. 5

    Department of Health and Human Services. 1997. Guidance for Industry: Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies in Vitro. FDA, Rockville, MD.

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Marshall, A. Getting the right drug into the right patient. Nat Biotechnol 16, 9–12 (1998). https://doi.org/10.1038/5141

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing